# Plasmodium Immunotherapy for Advanced Malignant Solid Tumors

> **NCT04165590** · PHASE1,PHASE2 · RECRUITING · sponsor: **CAS Lamvac Biotech Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Malignant Solid Tumor

## Interventions

- **OTHER:** Plasmodium immunotherapy

## Key facts

- **NCT ID:** NCT04165590
- **Lead sponsor:** CAS Lamvac Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-10-24
- **Primary completion:** 2024-04-30
- **Final completion:** 2026-10-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04165590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04165590, "Plasmodium Immunotherapy for Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04165590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*